Our team has extensive collective experience and knowledge in academic research, executive and corporate management, government and international trade. The managing partners of Pacific Channel’s US-based sister company
The Channel Group have formed, managed and grown entrepreneurial life sciences companies for decades.
Pacific Channel
Brent S. Ogilvie, BSc. (Bio.), MBA
Managing Director
Email: bogilvie@pacificchannel.com
Tel: 09 304 0868
- Founder and Managing Director of Pacific Channel Limited, which is a venture development and investment company specialising in technology and life science-based industries.
- Foundation CEO (Part-time) of Androgenix Limited, a biotechnology company that applies genomic technology for the development products with application in the world-wide livestock industry.
- Director of Ecodiesel Limited, which has developed a proprietary manufacturing process to convert tallow (purified animal fat) into biodiesel at a capital cost several-fold lower and at a lower operating cost than known alternative processes.
- Director of Somnaceutics Limited, which is developing a sleep enhancement tonic:
- Director of Breathe Easy Limited, which is developing a therapeutic for cystic fibrosis
- Director of SciTOX Limited, which is commercialising a bio-sensor based toxicity analysis device.
- Accredited broker for New Zealand Trade and Enterprise's Escalator Service.
- Trustee the Urban Eco-living Trust.
- Former NZ Consul & Trade Commissioner to New York - Life Sciences.
- Former industrial product manager for a global corporation; technical consultant to NZ start-ups
---------------------------------------------------------------------------------------------------------------------------
Robert G. Feldman, BSc, MB, BS, MSc, PhD
Executive Director
Email: robert.feldman@pacificchannel.com
- Executive Director at Pacific Channel Limited
- Chief Scientific Officer at Somnaceutics Ltd.
- Medical Doctor and PhD in microbiology/immunology
- 15 year experience in the biotechnology and healthcare sectors
- Founder/CEO/Senior VP of 5 companies including Microscience Ltd, Vmax Ltd, Riotech Pharmaceuticals Ltd., Paramount BioScience Inc. and FirstPoint Biotech Inc.
- Operational, strategic, fundraising and business development experience
---------------------------------------------------------------------------------------------------------------------------
Mitali Purohit, BSc. (Bio.), MBE. (Hons)
Research Analyst
Email: mitali.purohit@pacificchannel.com
Tel: 09 304 0866
- Mitali Purohit is a Research Analyst at Pacific Channel Limited
- Through Pacific Channel activities as a seed investor, Ms. Purohit serves as a Chief Operating Officer for Breathe Easy Ltd, a biotechnology company that is developing a treatment for Cystic Fibrosis
- Ms Purohit has experience in assessing investment opportunities and assisting early stage life-science and engineering based ventures to become investment ready
- Ms Purohit’s principal interest is in technology commercialization, especially opportunity analysis, marketing and business development
- Her Master’s thesis investigated ingredient co-branding as a strategy option for a New Zealand supplier of functional ingredients
---------------------------------------------------------------------------------------------------------------------------
The Channel Group LLC
Robert J. Beckman
- Managing Partner - The Channel Group
- Current Board Member of private and public medical companies, including EZ EM Corporation (Nasdaq: EZEM)
- Current Trustee of New York Medical College
- Founder and immediate past CEO of Intergen Company, a multinational life sciences company involved in pharmaceuticals, diagnostics, and discovery tools
- Former Vice President, Marketing Services and Vice President and General Manager of Biochemical and Diagnostic Division of Revlon Health Care
• A founder, past Chairman and long-term Board Member of BIO (Biotechnology Industry Organisation) and the New York Biotechnology Association
- Co-Author of Bold Steps – New Horizons , an analysis and plan for advancing Biotechnology in New Zealand
---------------------------------------------------------------------------------------------------------------------------
Allan R. Goldberg, Ph.D.
- Managing Partner - The Channel Group
- Founder of several start-ups, including Zystor Therapeutics, Inc., which received a venture financing of approximately US $10 million where he serves as a Member of the Board of Directors
- Member of the Board of Directors of SuperGen Inc. (NasdaqNM:SUPG)
- Former Professor of Virology at the Rockefeller University
- Founder, CSO and CEO of Innovir Laboratories, Inc., a biopharmaceutical company focused on development of RNA drugs Took Innovir public on Nasdaq.
- Co-Author of Bold Steps – New Horizons, an analysis and plan for advancing Biotechnology in New Zealand
---------------------------------------------------------------------------------------------------------------------------
Philip N. Sussman
- Managing Partner - The Channel Group
- Member of Senior Management (Head of Business Development, CFO, and CEO) at several life sciences companies including Perlegen Sciences, Inc., Memory Pharmaceuticals Corp., and Cadus Pharmaceutical Corp.
- Took company public on Nasdaq while CFO
- Completed strategic alliances with major pharmaceutical companies including AstaZeneca AB, Bristol-Myers Squibb Co., Eli Lilly & Co., GlaxoSmithKline plc, Pfizer Inc., Solvary Pharmaceuticals B.V., and Unilever plc, transactions that provided funding in excess of US $100 million
- Director of Business Development at Ciba-Geigy Corp.’s Pharmaceuticals Division
- Advisor to PsychoGenics Inc., Automated Cell, Inc., and SCIUS Capital Group LLC
---------------------------------------------------------------------------------------------------------------------------